Transplant rejection

This study tests whether treating donor corneal tissue with a special light-based process (cross-linking) before transplant can make it last longer and reduce rejection in people at high risk of graft failure. About 96 adults who need a high-risk cornea transplant will receive ei…

This early-stage trial tests a drug called fostamatinib in 30 adults who have developed donor-specific antibodies after a lung transplant. These antibodies can attack the new lung and raise the risk of death. Participants take fostamatinib or a placebo for 8 weeks, along with the…

This study tests whether the drug frexalimab can prevent kidney transplant rejection better than the standard drug tacrolimus. About 526 adults receiving their first kidney transplant will be randomly assigned to one of the two treatments and followed for up to 5 years. The main …

After a liver transplant, patients take tacrolimus to stop their immune system from rejecting the new organ, but the drug can cause kidney problems, high blood pressure, diabetes, and other side effects. Researchers at the University of Alberta are comparing a once-daily extended…

This study tests a new drug called VEL-101 in 120 kidney transplant patients. The goal is to see if VEL-101 can safely replace the standard drug tacrolimus, which often causes side effects. Researchers will monitor for rejection, side effects, and how the drug behaves in the body…

This study tests if a new drug called siplizumab can safely prevent kidney transplant rejection better than the current standard treatment. About 120 adults receiving a kidney transplant will be split into three groups: two groups get different doses of siplizumab, and one gets t…

After a kidney or kidney-pancreas transplant, the body may attack the new organ—a problem called acute T cell mediated rejection. Doctors use strong steroids to stop this, but there's no standard dose, and too much can cause serious side effects. This phase 3 trial will enroll 54…

This early-stage trial tests a drug called siltuximab in 30 lung transplant patients who are experiencing antibody-mediated rejection, a serious condition that often leads to transplant failure. The drug is added to standard rejection treatment to see if it is safe and tolerable.…

This early-stage trial tests two drugs, carfilzomib and belatacept, in 25 kidney transplant recipients who have a type of rejection called antibody-mediated rejection. The goal is to see if the combination is safe and can reduce harmful antibodies or improve kidney function over …

This study tests a mobile app that lets teen heart transplant patients record themselves taking their anti-rejection medication. The goal is to improve medication adherence and reduce the risk of organ rejection and hospital stays. About 100 teens aged 10-21 who have had a heart …

This study looks at whether a treatment called extracorporeal photopheresis can help kidney transplant recipients whose bodies are rejecting the new organ. The treatment involves filtering the patient's blood, treating it with a light-activated drug, and returning it to the body.…

This Phase 3 trial tests an oral drug called belumosudil in adults who have chronic lung allograft dysfunction (CLAD) after a bilateral lung transplant. CLAD is a form of chronic rejection that slowly worsens lung function. The study compares belumosudil to a placebo, both given …

This phase 3 trial compares two induction therapies—rabbit anti-thymocyte globulin (rATG) and basiliximab—in 244 sensitized kidney transplant recipients who do not have pre-existing donor-specific antibodies. The goal is to see which drug better prevents biopsy-proven acute rejec…

This study tests whether monitoring levels of a harmless virus called TTV can help doctors personalize immune-suppressing drugs for kidney transplant patients. The goal is to prevent long-term complications like infections, cancer, and organ rejection. About 600 adults who receiv…

This early-stage trial tests whether giving a special mix of blood cells after an organ transplant can help the body accept the new organ without needing lifelong anti-rejection drugs. About 10 children and adults receiving kidney, lung, or intestinal transplants will get the cel…

This study tests whether giving a kidney transplant recipient blood stem cells from their sibling donor can train the body to accept the new kidney without lifelong anti-rejection drugs. Fifteen adults receiving a kidney from an identical sibling will get a conditioning regimen o…

This phase 2 trial tests whether a single infusion of a patient's own regulatory T cells (TRK-001) can prevent the immune system from attacking a new kidney. 34 living-donor kidney transplant recipients will either receive standard anti-rejection drugs alone or those drugs plus t…

This early-phase trial at Mayo Clinic is testing whether it is possible to transplant a bladder along with a kidney in people who have kidney failure due to bladder problems. Up to 30 participants will receive both organs from a deceased donor. The goal is to see if the bladder w…

This study tests whether taking immunosuppressant drugs just once daily after a liver transplant is as safe and effective as the standard twice-daily schedule. The goal is to make it easier for patients to stick with their lifelong medication, which could improve their quality of…

This study tests whether adding the drug tocilizumab to standard treatment (plasmapheresis, IVIG, and rituximab) can better treat chronic active antibody-mediated rejection in kidney transplant recipients. About 50 participants will be enrolled to see if the combination improves …

This early-stage study tests whether a drug called emapalumab can prevent the body from rejecting a stem cell transplant. The study will include 20 patients who are at high risk for rejection. Researchers will also study how the drug works in the body to improve future treatments…

This early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…

This study tests whether a newer drug, letermovir, is safer and more effective than the standard valganciclovir for preventing CMV infection in heart transplant recipients. About 150 moderate- to high-risk adults will be enrolled. The main focus is on reducing side effects like l…

This study tests whether a blood test that measures donor DNA (dd-cfDNA) can safely guide follow-up care for kidney transplant patients, potentially reducing the need for invasive biopsies. 500 adult kidney transplant recipients will be randomly assigned to standard care or a str…

This study is testing whether a blood or urine test can detect kidney transplant rejection earlier and more easily than the current standard, which requires a biopsy. The test looks for DNA from the transplanted kidney in the blood or urine, which may increase when rejection occu…

This study looks at whether proteins carried by tiny particles called extracellular vesicles in the blood can signal when a heart transplant is being rejected. Researchers will track 30 heart transplant patients over 15 months, comparing protein patterns in those with and without…

This study at Mayo Clinic is testing whether an artificial intelligence (AI) program can detect heart transplant rejection using standard tests like ECG and ultrasound. Researchers will enroll 500 heart transplant patients and compare the AI's findings to biopsy results. If it wo…

This study is testing whether a simple blood test called Prospera can detect heart transplant rejection as accurately as the current standard—a biopsy of the heart. Researchers will compare the blood test results with biopsy results and antibody levels in 300 heart transplant rec…

This study is testing whether a blood test (called DD-cfDNA) can accurately detect kidney transplant rejection, potentially replacing the need for invasive kidney biopsies. Researchers will compare the blood test results with standard biopsy analysis in 300 kidney transplant reci…

This study is testing whether a blood test that measures donor DNA can detect rejection in heart transplant patients. Researchers will compare the test results with standard heart biopsies in 120 adults across Sweden. If the test works well, it could offer a less invasive way to …

This study explores whether a special cardiac MRI can detect complications after heart transplantation without the need for invasive biopsies or angiography. Researchers will scan 247 adults and children, including healthy volunteers and transplant recipients, to see if MRI measu…

This study tests whether a special MRI using inhaled xenon gas can detect early signs of rejection in lung transplant patients. Researchers will compare MRI images with lung tissue samples and breathing tests in 60 participants. The goal is to find a safer, non-invasive way to di…

This study is looking at whether changes in platelet function can signal acute rejection in kidney transplant recipients. Researchers will measure platelet activity before and after transplant, and at times of suspected rejection. The goal is to develop a non-invasive blood test …

This study is testing whether a donor-derived cell-free DNA (dd-cfDNA) test can accurately detect rejection in kidney transplant recipients. Researchers will compare the test results to standard biopsy findings in 125 adults who are at least 12 days post-transplant. If the test w…

This study is testing a new blood test to quickly identify damage or infection in lung transplant patients. Researchers will take blood samples at regular times and when problems occur, then compare the results to standard tests. The goal is to make diagnosis faster and easier, w…

Children who receive a heart transplant need powerful drugs to stop their immune system from attacking the new organ. Researchers are testing a different approach: they collect regulatory T cells, a type of immune cell that dampens rejection, from thymus tissue that is normally d…

This study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…

This study is looking at tiny molecules called microRNAs in the blood of children who have had a heart transplant. The goal is to find patterns that can predict which children are at risk for infection or rejection of the new heart. By understanding these patterns, doctors hope t…

This study looks at whether cardiac MRI and blood tests can detect acute rejection in children and young adults who have had a heart transplant. Currently, doctors often use invasive heart biopsies to check for rejection, which can be uncomfortable and risky. The goal is to see i…

This study is looking for tiny molecules in the blood called microRNAs that can help doctors tell if a heart transplant patient's immune system is too active (causing rejection) or too weak (causing infection). Researchers will follow 250 adult heart transplant recipients for one…

This study will collect medical information, blood samples, and patient feedback from 2,600 lung transplant candidates, donors, and recipients. The goal is to learn how different care practices affect outcomes like rejection, infection, and survival. Researchers hope to find biom…

This study aims to understand why some people who get a lung transplant develop rejection while others do not. Researchers will follow 100 adults aged 18 to 75 who have progressive lung disease or have had or may get a lung transplant. Participants will have regular check-ups, bl…

This study aims to see if a blood test (dd-cfDNA) can accurately detect when a lung transplant is being rejected, compared to the standard method of taking a tissue sample (biopsy). Researchers will enroll 600 adult lung transplant recipients to compare blood test results with bi…

This study looks for early signs that a treatment called ECP is working in people who have had a lung transplant and developed chronic rejection (CLAD). Researchers will collect blood samples and, for some, lung MRI scans before, during, and after ECP therapy. The goal is to find…

This study aims to see if a new molecular test can better detect rejection in heart transplant patients compared to standard biopsy analysis. Researchers will collect extra biopsy samples from 900 participants and analyze them using the Molecular Microscope Diagnostic System. The…

This study looks at lung transplant biopsies to see if molecular testing can better diagnose rejection. Researchers will collect biopsy samples from 700 lung transplant recipients and analyze them using a molecular classifier. The goal is to improve accuracy and potentially devel…

This study looks at 683 heart transplant patients to see if advanced heart scans (CMR) and blood tests can detect antibody-mediated rejection, a common complication. Participants must be stable and at least one year post-transplant. The goal is to find non-invasive ways to diagno…

This study looks at why some transplanted hearts stop working well over time. Researchers will use heart MRI scans and advanced cell analysis to find early signs of trouble in 376 heart transplant patients. The goal is to better understand the causes of graft dysfunction so docto…

This study compares two biopsy methods—a standard forceps and a new miniature cryoprobe—to see which better detects rejection in lung transplant recipients. About 100 participants will be randomly assigned to one method during their scheduled biopsy. The goal is to find which tec…

This study looks at a thin layer inside blood vessels, called the glycocalyx, in people who have been declared brain dead and are organ donors. Researchers want to see if damage to this layer affects how well donated organs work after transplant. By understanding this, they hope …

This study looks at why some kidney transplant rejections don't respond to treatments that target B cells. Researchers will collect blood, stool, and kidney tissue from 45 patients to study B cell behavior and antibody reactions. The goal is to uncover the hidden triggers of reje…

This study tracks 15 people getting a simultaneous liver-kidney transplant to see how much their own kidneys recover. Researchers use a special nuclear scan and blood tests to measure kidney function before and after transplant. The goal is to create a way to predict who might no…

This study collects white blood cells from up to 10 healthy volunteers and patients with autoimmune diseases, inflammation, or liver transplant. The goal is to analyze these cells to help develop engineered regulatory T cell (Treg) therapies. No treatment is given; it is a resear…

This study explores whether a special type of MRI, called manganese-enhanced MRI, can help identify people with kidney disease who are at risk for heart problems. Researchers will scan the heart and kidneys of 120 adults with various kidney conditions, including acute kidney inju…

This study is testing a new way to monitor heart transplant patients for rejection using a simple catheter-based measurement called IMR. The goal is to see if this test can identify high-risk patients and reduce the need for invasive biopsies. Researchers will follow 100 heart tr…

This study involves 135 adults getting a cornea transplant. Surgeons will use a new method to check the health of donor eye tissue before surgery. The goal is to see if this check helps predict how well the transplant will work long-term, reducing the chance of graft failure.

This study aims to understand why the immune system sometimes rejects a transplanted uterus. Researchers will analyze blood, tissue, and swab samples from 30 women who have received or will receive a uterine transplant, as well as from donors and healthy volunteers. The goal is t…